$DNLI Income Statement | Understand Stock

$DNLI

$18.66 +$0.25 (1.36%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Collaboration revenue:
Collaboration revenue from customers
Other collaboration revenue
Total collaboration revenue
Operating expenses:
Research and development expense
General and administration
Total operating expenses
Gain from divestiture of small molecule programs
Loss from operations
Interest and other income, net
Loss before income taxes
Income tax expense
Net loss
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable securities, net of tax
Comprehensive loss
Net loss per share, basic (usd per share)
Net loss per share, diluted (usd per share)
Weighted average number of shares outstanding, basic (in shares)
Weighted average number of shares outstanding, diluted (in shares)

Comments